August 5, 2020/by ksmithAmplyx Pharmaceuticals Announces Participation in Multiple Upcoming Investor Conferences
July 22, 2020/by ksmithAmplyx Announces Positive Top-line Data in Phase 2 Clinical Trial of Novel Antifungal Fosmanogepix
June 24, 2020/by ksmithAmplyx Pharmaceuticals to Present at the Upcoming Virtual European Biotech Investor Day 2020
May 19, 2020/by ksmithAmplyx Pharmaceuticals Adds Pfizer and Adage to Series C Financing, Bringing Total to over 90 Million
April 29, 2020/by ksmithAmplyx Pharmaceuticals to Participate in Antifungal Panel at Maxim Group’s Infectious Disease Virtual Conference: The Renaissance of the Anti-infective Sector
September 24, 2019/by eallisonAmplyx Announces Presentations on Fosmanogepix (APX001) at IDWeek 2019 and the 9th Congress on Trends in Medical Mycology (TIMM-9)
September 16, 2019/by eallisonAmplyx Pharmaceuticals Licenses Phase 2 Drug Candidate for BK Viral Disease in Transplant Patients
September 16, 2019/by eallisonAmplyx Pharmaceuticals Announces Positive Preliminary Data from Ongoing Fosmanogepix Phase 2 Study in Candidemia
September 9, 2019/by eallisonFDA Grants Fast Track Status to Amplyx Pharmaceuticals for IV and Oral Formulations of Fosmanogepix (APX001) for Seven Different Indications
April 12, 2019/by Lauren FishAmplyx Pharmaceuticals Announces Presentations at the 29th ECCMID in Amsterdam
February 11, 2019/by eallisonFDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Cryptococcosis
November 12, 2018/by eallisonAmplyx Doses First Patient in Phase 2 Trial of APX001 in Patients with Candida Infection
June 7, 2018/by eallisonAmplyx Announces Presentations on APX001 at American Society for Microbiology Microbe 2018 and the 20th Symposium on Infections in the Immunocompromised Host
June 5, 2018/by eallisonAmplyx Pharmaceuticals to Participate in BIO International Convention Panel and Present at Jefferies Global Healthcare Conference
April 30, 2018/by eallisonAmplyx Pharmaceuticals Demonstrates APX001 has Potent Activity Against Deadly Multidrug-Resistant Candida Species
November 12, 2018/by eallisonAmplyx Doses First Patient in Phase 2 Trial of APX001 in Patients with Candida Infection
June 7, 2018/by eallisonAmplyx Announces Presentations on APX001 at American Society for Microbiology Microbe 2018 and the 20th Symposium on Infections in the Immunocompromised Host
June 5, 2018/by eallisonAmplyx Pharmaceuticals to Participate in BIO International Convention Panel and Present at Jefferies Global Healthcare Conference
April 30, 2018/by eallisonAmplyx Pharmaceuticals Demonstrates APX001 has Potent Activity Against Deadly Multidrug-Resistant Candida Species
September 24, 2019/by eallisonAmplyx Announces Presentations on Fosmanogepix (APX001) at IDWeek 2019 and the 9th Congress on Trends in Medical Mycology (TIMM-9)
September 16, 2019/by eallisonAmplyx Pharmaceuticals Licenses Phase 2 Drug Candidate for BK Viral Disease in Transplant Patients
September 16, 2019/by eallisonAmplyx Pharmaceuticals Announces Positive Preliminary Data from Ongoing Fosmanogepix Phase 2 Study in Candidemia
September 9, 2019/by eallisonFDA Grants Fast Track Status to Amplyx Pharmaceuticals for IV and Oral Formulations of Fosmanogepix (APX001) for Seven Different Indications
April 12, 2019/by Lauren FishAmplyx Pharmaceuticals Announces Presentations at the 29th ECCMID in Amsterdam
February 11, 2019/by eallisonFDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Cryptococcosis
August 5, 2020/by ksmithAmplyx Pharmaceuticals Announces Participation in Multiple Upcoming Investor Conferences
July 22, 2020/by ksmithAmplyx Announces Positive Top-line Data in Phase 2 Clinical Trial of Novel Antifungal Fosmanogepix
June 24, 2020/by ksmithAmplyx Pharmaceuticals to Present at the Upcoming Virtual European Biotech Investor Day 2020
May 19, 2020/by ksmithAmplyx Pharmaceuticals Adds Pfizer and Adage to Series C Financing, Bringing Total to over 90 Million
April 29, 2020/by ksmithAmplyx Pharmaceuticals to Participate in Antifungal Panel at Maxim Group’s Infectious Disease Virtual Conference: The Renaissance of the Anti-infective Sector
August 5, 2020/by ksmithAmplyx Pharmaceuticals Announces Participation in Multiple Upcoming Investor Conferences
July 22, 2020/by ksmithAmplyx Announces Positive Top-line Data in Phase 2 Clinical Trial of Novel Antifungal Fosmanogepix
June 24, 2020/by ksmithAmplyx Pharmaceuticals to Present at the Upcoming Virtual European Biotech Investor Day 2020
May 19, 2020/by ksmithAmplyx Pharmaceuticals Adds Pfizer and Adage to Series C Financing, Bringing Total to over 90 Million
April 29, 2020/by ksmithAmplyx Pharmaceuticals to Participate in Antifungal Panel at Maxim Group’s Infectious Disease Virtual Conference: The Renaissance of the Anti-infective Sector
September 24, 2019/by eallisonAmplyx Announces Presentations on Fosmanogepix (APX001) at IDWeek 2019 and the 9th Congress on Trends in Medical Mycology (TIMM-9)
September 16, 2019/by eallisonAmplyx Pharmaceuticals Licenses Phase 2 Drug Candidate for BK Viral Disease in Transplant Patients
September 16, 2019/by eallisonAmplyx Pharmaceuticals Announces Positive Preliminary Data from Ongoing Fosmanogepix Phase 2 Study in Candidemia
September 9, 2019/by eallisonFDA Grants Fast Track Status to Amplyx Pharmaceuticals for IV and Oral Formulations of Fosmanogepix (APX001) for Seven Different Indications
April 12, 2019/by Lauren FishAmplyx Pharmaceuticals Announces Presentations at the 29th ECCMID in Amsterdam
February 11, 2019/by eallisonFDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Cryptococcosis
November 12, 2018/by eallisonAmplyx Doses First Patient in Phase 2 Trial of APX001 in Patients with Candida Infection
June 7, 2018/by eallisonAmplyx Announces Presentations on APX001 at American Society for Microbiology Microbe 2018 and the 20th Symposium on Infections in the Immunocompromised Host
June 5, 2018/by eallisonAmplyx Pharmaceuticals to Participate in BIO International Convention Panel and Present at Jefferies Global Healthcare Conference
April 30, 2018/by eallisonAmplyx Pharmaceuticals Demonstrates APX001 has Potent Activity Against Deadly Multidrug-Resistant Candida Species
